Breaking News

New radiopharmaceutical heads to the FDA after Phase 3 win

March 7, 2025
Hey Cancer Briefing readers. Sharing that for a limited time only, you can get 50% off an annual STAT+ subscription. A pretty good deal if you ask me. Anyway, thanks for reading and hope you are taking care. —Alexa Lee, newsletter strategist
Scott Olson/Getty Images

Using oil, seed oils included, instead of butter lowered risk of premature death, says study

Despite concern about "seed oils," a study in JAMA Internal Medicine makes a case for oils like canola, along with olive oil, over butter.

By Sarah Todd


STAT+ | Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

The drug, called dordaviprone, has been submitted to the FDA for accelerated approval, with a decision expected by Aug. 18.

By Jason Mast


STAT+ | FDA scolds drugmaker over promotion that touts 'misleading' comparison with generics

The agency said an Edenbridge Pharmaceuticals' promotional panel falsely maintained there was greater patient adherence to its drug compared with generics.

By Ed Silverman



Adobe

STAT+ | New radiopharmaceutical heading to the FDA after Phase 3 win

The drug from ITM Isotope Technologies Munich SE has been developed as a treatment for gastroenteropancreatic neuroendocrine tumors.

By Allison DeAngelis


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments